Kraut E, Frey EK, Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seyler’s Zeitschrift für Physiologische Chemie 1930; 192: 1–21.
Kunitz M, Northrup JH. Isolation rom beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor trypsin compound. J Gen Physiol 1936; 19: 991–1007.
Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236–61.
Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987 Dec 5; 2: 1289–91.
van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on haemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640–5.
Royston D. High-dose aprotinin therapy: a review of the first. five years’ experience. J Cardiothorac Vasc Anesth 1992 Feb; 6: 76–100.
Edmunds LH, Addonizio VP. Extracorporeal circulation. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: Lippencott, 1987: 901–912.
Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11: 249–80.
Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680–97.
Kirklin JK, Westaby S, Blackstone JW, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845–57.
Westaby S. Complement and the damaging effects of cardiopulmonary bypass. Thorax 1983; 38: 321–5.
Edmunds LH, Colman RW, Niewiarowski S. Blood-surface interactions during cardiopulmonary bypass. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 27–36.
Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800–6.
Kluft C. Pathomechanisms of defective hemostasis during and after extracorporeal circulation: contact phase activation. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 10–15.
Bachmann F, McKenna R, Cole ER, et al. The hemostatic mechanism after open heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J Thorac Cardiovasc Surg 1975; 70: 76–85.
Holloway DS, Summaria L, Sandesara J, et al. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62–7.
Kucuk O, Kwaan HC, Frederickson J, et al. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol 1986; 23: 223–9.
Stibbe J, Kluft C, Brommer EJP, et al. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375–82.
Michelson AD. Pathomechanism of defective hemostasis during and after extrcorporeal circulation: The role of platelets. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 16–26.
Shattil SJ, Hoxie JA, Cunningham M, et al. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107–14.
Musial J, Niewiarowski S, Hershock D, et al. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985; 105: 514–22.
Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314: 1446–8.
Bidstrup BP, Royston D, Sapsford RN, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989 Mar; 97: 364–72.
Alajmo F, Calamai G, Perna AM, et al. High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989 Oct; 48: 536–9.
Biagini A, Comite C, Russo V, et al. High dose aprotinin to reduce blood loss in patients undergoing redo open heart surgery. Acta Anaesthesiol Belg 1992; 43: 181–6.
Campbell FW, Jobes DR, Ellison N. Coagulation management during and after cariopulmonary bypass. In: Hensley FA, Martin DE, editors. The practice of cardiac anesthesia. Boston/Toronto/London: Little, Brown and Company, 1990: 546–579.
Orchard MA, Goodchild CS, Prentice CRM, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533–41.
van den Dungen JJ, Karliczek GF, Brenken U, et al. Clinical study of blood trauma during perfusion with membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982; 83: 108–16.
Masters RG. Bubble oxygenators are outdated and no longer appropriate for cardiopulmonary bypass. Pro: the superiority of the membrane oxygenator. J Cardiothor Anesth 1989; 3: 235–7.
Adelman B, Michelson AD, Greenberg J, et al. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood 1986; 68: 1280–4.
Stricker RB, Wong D, Shiu DT, et al. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: Effects on surface proteins and platelet aggregation. Blood 1986; 68: 275–80.
Wenger RK, Lukasiewicz H, Mikuta BS, et al. Loss of platelet fibrinogen receptors during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 97: 235–9.
Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel Forschung 1983; 33: 479–94.
Lu H, Soria C, Commin P-L, et al. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633–7.
Havel M, Teufelsbauer H, Knobl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991 Jun; 101: 968–72.
Vandenvelde C, Fondu P, Dubois-Primo J. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass [letter]. Lancet 1991 May 11; 337: 1157–8.
Marx G, Pokar H, Reuter H, et al. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991 Oct; 5: 467–74.
Kawasuji M, Ueyama K, Sakakibara N, et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 1205–9.
Longstaff C. Studies in the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994; 5: 537–42.
Feindt P, Volkmer I, Seyfert U, et al. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy. Thorac Cardiovasc Surg 1993 Feb; 41: 9–15.
Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990 Dec; 73: 1119–26.
Bailey CR, Wielogorski AK. Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J 1994; 71: 349–53.
Mohr R, Goor DA, Lusky A, et al. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation 1992 Nov; 86 (5 Suppl): II405–9.
Covino E, Pepino P, Iorio D, et al. Low dose aprotinin as blood saver in open heart surgery. Eur J Cardiothorac Surg 1991; 5: 414–8.
Lavee J, Raviv Z, Smolinsky A, et al. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993 Jan; 55: 114–9.
Liu B, Belboul A, Rådberg G, et al. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1993; 27: 149–55.
van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788–97.
Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor blood transfusion in patients undergoing repeat coronary artery bypass grafting. Miles data on file.
Spannagl M, Dietrich W, Beck A, et al. High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial infarction [letter]. Thromb Haemost 1994; 72: 159–60.
Nagaoka H, Innami R, Murayama F, et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg Torino 1991 Jan-Feb; 32: 31–7.
John LCH, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 1993 May; 55: 1175–9.
Kestin AS, Valeri R, Shukri KF, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107–17.
Cramer EM, Lu H, Caen JP, et al. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991; 77: 694–9.
Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993 Jul; 106: 1–10.
Fraedrich G, Neukamm K, Schneider T, et al. Safety and risk/benefit assessment of aprotinin in primary CABG. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 221–231.
Blauhut B, Gross C, Necek S, et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958–67.
Kaller H, Patzschke K, Wegner LA, et al. Pharmacokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers. Eur J Drug Metab 1978; 2: 79–85.
Levy JH, Bailey JM, Salmenperä M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80: 1013–8.
Schall R, Groenewoud G, Hundt HKL, et al. Pharmacokinetic profile of aprotinin (Trasylol) in female patients undergoing primary elective hysterectomy. Drug Invest 1992; 4 (4): 292–9.
Schall R, Müller FO, Hundt HKL, et al. Pharmacokinetic profile of high doses of aprotinin in patients undergoing primary elective hysterectomy: a meta-analysis of two clinical trials. Drug Invest 1994 Apr; 7: 200–8.
Miles. Aprotinin prescribing information. West Haven, Connecticut, USA, 1994.
Jochum M, Jonáková V, Dittmer H, et al. An enzymatic assay convenient for the control of aprotinin levels during proteinase inhibitor therapy. Fresenius Z Anal Chem 1984; 317: 719–20.
Müller-Esterl W. Drugs monitored during therapy: Aprotinin, drugs and pesticides. In: Bergmeyer HU, editor. Methods of enzymatic analysis. Weinheim: VerlagsgesellschaftmbH, 1986: 246–256.
Trautschold I, Werle E, Zickgraf-Rüdel G. Trasylol. Biochem Pharmacol 1967; 16: 59–72.
Emerson TE. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 1989; 7: 127–40.
Clasen C, Jochum M, Mueller-Esterl W. Feasability study of very high dose aprotinin in polytrauma patients. In: Schlag G, Redl H, editors. First Vienna Shock Forum:pathophysiological role of mediators and mediator inhibitors in shock. New York: Liss, 1987: 175–183.
Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543–53.
Baele PL, Ruiz-Gomez J, Londot C, et al. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg 1992; 43: 103–12.
Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993 Jan; 105: 147–52.
Dietrich W, Barankay A, Hähnel C, et al. High-dose aprotinin in cardiac surgery: three years’ experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992 Jun; 6: 324–7.
Harder MP, Eijsman L, Roozendaal KJ, et al. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991 Jun; 51: 936–41.
Swart MJ, Gordon PC, Hayse-Gregson PB, et al. High-dose aprotinin in cardiac surgery-a prospective, randomized study. Anaesth Intensive Care 1994; 22: 529–33.
Lytle BW, Loop FD, Cosgrove DM, et al. Fifteen hundred coronary reoperations: results and determinants of early and late survival. J Thorac Cardiovasc Surg 1987; 93: 847–59.
Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor drug trial in coronary artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982; 307: 73–8.
Ferraris VA, Ferraris SP, Lough FC, et al. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg 1988; 45: 71–4.
Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 1990; 15: 15–20.
Bashein G, Nessly ML, Rice AL, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991; 151: 89–93.
Bidstrup BP, Royston D, McGuinness C, et al. Aprotinin in aspirin-pretreated patients. Perfusion 1990; 5 Suppl.: 77–81.
Liu B, Belboul A, al-Khaja N, et al. High-dose aprotinin (Trasylol) in reducing bleeding and protecting lung function in potential bleeders undergoing cardiopulmonary bypass. Chin Med J Engl 1991; 104: 980–5.
Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994; 107: 554–61.
Bertrand P, Mazzucotelli JP, Loisance D, et al. L’aprotinine en chirurgie cardiaque chez les patients sous antiagrégants plaquettaires. Arch Mal Coeur Vaiss 1993; 86: 1471–4.
Schönberger JP, Bredee JJ, van Oeveren W, et al. Preoperative therapy of low-dose aspirin in internal mammary artery bypass operations with and without low-dose aprotinin. J Thorac Cardiovasc Surg 1993; 106: 262–7.
Tabuchi N, van Oeveren W, Eijsman L, et al. Preserved hemostasis during the combined use of aprotinin and aspirin in CABG operations. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 245–251.
CosgroveIII DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992 Dec; 54: 1031–8.
Havel M, Grabenwöger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807–10.
Schönberger JP, Everts PA, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving. Ann Thorac Surg 1992; 54: 1172–6.
Schönberger JP, van Zundert A, Bredée JJ, et al. Blood loss and use of blood in internal mammary artery and saphenous vein bypass grafting with and without adding a single, low-dose of aprotinin (2 million units) to the pump prime. Acta Anaesthesiol Belg 1992; 43: 187–96.
Lytle BW, Cosgrove DM, Loop FD, et al. Perioperative risk of bilateral internal mammary artery grafting: analysis of 500 cases from 1971 to 1984. Circulation 1986; 74 Suppl. 3: 37–41.
Henze A, Ramström J, Nyström SO. Bilateral internal mammary artery for coronary revascularization. Early experience of 100 cases. Scand J Thorac Cardiovasc Surg 1989; 23: 9–12.
Hardy J-F, Desroches J, Belisle S, et al. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993; 40: 625–31.
o’Regan DJ, Giannopoulos N, Mediratta N, et al. Topical aprotinin in cardiac operations. Ann Thorac Surg 1994; 58: 778–81.
Scott DHT, Au J. The Edinburgh experience-low-dose Trasylol. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 263–265.
Tatar H, Cicek S, Demirkilic U, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993 Mar; 55: 659–61.
Popov-Cenic S, Urban AE, Noë G. Studies on the cause of bleeding during and after surgery with heart-lung machine in children with cyanotic and acyanotic congenital cardiac defects and their prophylactic treatment. In: McConn R, editor. Role of chemical mediators in the pathophysiology of acute illness and injury. New York: Raven, 1982: 229–42.
Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993 Jun; 55: 1460–6.
Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993 Apr; 105: 705–11.
Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993 Apr; 105: 712–20.
Herynkopf F, Lucchese F, Pereira E, et al. Aprotinin in children undergoing correction of congenital heart defects. J Thorac Cardiovasc Surg 1994; 108: 517–21.
Müller H, Alken A, Ziemer G, et al. Aprotinin in paediatric cardiopulmonary bypass surgery. J Cardiothor Anesth 1992; 6.
Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993 Apr; 55: 971–6.
Laub GW, Riebman JB, Chen C, et al. The impact of aprotinin on coronary artery bypass graft patency. Chest 1994; 106: 1370–5.
Jegaden O, Vedrinne C, Rossi R. Aprotinin does not compromise arterial graft patency in coronary bypass operations [letter]. J Thorac Cardiovasc Surg 1993 Jul; 106: 180–1.
Lemmer Jr. JH, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypasss grafting: effect on postoperative renal function. Ann Thorac Surg 1995; 59: 132–6.
Sundt TM 3d, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993 Jun; 55: 1418–24.
Smith CR, Mongero LB, DeRosa CM, et al. Safety of aprotinin in profound hypothermia and circulatory arrest. Ann Thorac Surg 1994; 58: 606–7.
Levy JH. Antibody formation after drug administration during cardiac surgery: parameters for aprotinin use. J Heart Lung Transplant 1993 Jan-Feb; 12 (1 Pt 1): S26–33.
Ruskowski H, Joos A, Kiefer H, et al. Untersuchungen zur antigenität von Trasylol in der offenen herzchirurgie. Thorac Cardiovasc Surg 1993; 41 Suppl. 1: 142.
Beckmann H, Mayer G. Allergic/anaphylactic reaction in patients with cardiac reoperation and Trasylol re-exposition-retrospective analysis in 2 cardiosurgical units-statistical report. Bayer data on file. 1994.
Schulze K, Graeter T, Schaps D, et al. Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg 1993; 7: 495–6.
Lorenz W, Duda D, Dick W, et al. Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 1994; 343: 933–40.
Overlack A, Stumpe KO, Küehnert M, et al. Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition. Klin Wochenschr 1981; 59: 69–74.
Clozel J-P, Banken L, Roux S. Aprotinin: an antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo. J Am Coll Cardiol 1990; 16: 507–10.
Fears R, Greenwood H, Hearn J, et al. Inhibition of the fibrinolytic and fibrinogenolytic activity of plasminogen activators in vitro by the antidotes -aminocaproic acid, tranexamic acid and aprotinin. Fibrinolysis 1992 Apr; 6: 79–86.
Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992; 86 Suppl. 2: II410–2.
Najman DM, Walenga JM, Fareed J, et al. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993 Mar; 55: 662–6.
Wendel HP, Heller W, Gallimore MJ, et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993 Feb; 4: 41–5.
Wang J-S, Lin C-Y, Hung W-T, et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992 Dec; 77: 1080–4.
Royston D, Bidstrup BP, Taylor KM, et al. Reduced blood loss following open heart surgery with aprotinin (Trasylol) is associated with an increase in intraoperative activated clotting time (ACT). J Cardiothorac Anesth 1989 Oct; 3 (5 Suppl 1): 80.
de Smet AA, Joen MC, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990 Oct; 100: 520–7.
Farooqi N, De Hert S, Vlaeminck A, et al. Effects of low doses of aprotinin on clotting times activated with celite and kaolin. Acta Anaesth Belg 1993; 44: 87–92.
Marggraf G, Schax H, Trübenbach H, et al. Evolutin of requirements to replace blood and plasma in cardiac surgery. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 78–83.
Bhattacharya SK, Sharma GP, Polimeni PI, et al. Intraoperative blood conservation using cell-saver. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 178–18.
von der Emde J, Mahmoud FO, Esperer HD. Retransfusion of postoperative drainage blood. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 129–132.
Sons H, Schulte HD, Bircks W. Preoperative autologous blood donation to minimize homologous blood transfusions. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 160–163.
Donauer E, Babik B, Mészáros E, et al. Use of predonated autologous blood in cardiac surgery. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 164–170.
Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. Arandomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994; 108: 99–108.
Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70–4.
Horrow JC, Van Riper DF, Strong MD, et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063–70.
Vander Salm TJ, Ansell JE, Okike ON, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double blind randomised study. J Thorac Cardiovasc Surg 1988; 95: 538–40.
DelRossi AJ, Cernaianu AC, Botros S, et al. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989; 96: 27–30.
Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 1992 Apr; 39: 353–65.